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RESEARCH ARTICLE Open Access
Defining cognitive impairment in people-
living-with-HIV: the POPPY study
Davide De Francesco1* , Jonathan Underwood2, Frank A. Post3, Jaime H. Vera4, Ian Williams5, Marta Boffito6,
Memory Sachikonye7, Jane Anderson8, Patrick W. G. Mallon9, Alan Winston2, and Caroline A. Sabin1 on behalf of
the POPPY study group
Abstract
Background: The reported prevalence of cognitive impairment (CI) varies widely in cohorts of people living with HIV
(PLWH); this may partly be due to the use of different diagnostic criteria. Agreement between diagnostic criteria of CI, the
optimal definition to use, and associations with patient-reported cognitive symptoms have not been fully investigated.
Methods: Two hundred ninety PLWH aged >50 years and 97 matched negative controls completed a detailed
assessment of cognitive function and three questions regarding cognitive symptoms. Age- and education-adjusted test
scores (T-scores) determined if subjects met the following definitions of CI: Frascati, global deficit score (GDS) and the
multivariate normative comparison (MNC) method.
Results: PLWH were more likely than controls to meet each definition of CI (ORs were 2.17, 3.12 and 3.64 for Frascati,
GDS and MNC, respectively). Agreement of MNC with Frascati and GDS was moderate (Cohen’s k = 0.42 and 0.48,
respectively), whereas that between Frascati and GDS was good (k = 0.74). A significant association was found between all
the three criteria and reporting of memory loss but not with attention and reasoning problems. The 41 (14 %) PLWH
meeting all the three criteria had the lowest median global T-score (36.9) and highest rate of symptom reporting (42 %).
Conclusions: Different CI criteria show fair diagnostic agreement, likely reflecting their ability to exclude CI in the same
group of individuals. Given the lower overall cognitive performance and higher rates of symptom reporting in those
meeting all three criteria of CI, further work assessing this as a definition of CI in PLWH is justified.
Keywords: HIV, Cognitive impairment, Patient-reported cognitive symptoms, Neurology, HIV-associated
neurocognitive disorder
Background
In recent years, despite the introduction of combination
antiretroviral therapy (ART), a high but varying prevalence
of cognitive impairment (CI) has been reported among
HIV-positive individuals. Robertson et al. [1] described a
26 % prevalence of CI among HIV-positive subjects who
had received ART for at least 20 weeks, while Heaton et al.
[2] reported a prevalence of 36 % among ART-treated
asymptomatic individuals. Among those with long-standing
viral suppression, Winston et al. [3] and Simioni et al. [4]
reported prevalences of 51 and 74 %, respectively.
The optimal screening tools to identify CI are unknown.
The current European AIDS Clinical Society (EACS) guide-
lines recommend three questions as one form of assess-
ment to guide the initial evaluation of HIV-positive
individuals with suspected cognitive problems [5]. These
patient-reported measures may be a quick and practical
method of screening for cognitive impairment in clinical
practice, however, doubts about their utility remain [6].
When cognitive function is assessed through objective
neuropsychological tests, differences in the reported preva-
lence of CI may be due to the use of different diagnostic
criteria. Three criteria in current use include the ‘Frascati’
criteria, proposed by Antinori et al. [7] and also known as
HIV-associated neurocognitive disorder (HAND) criteria,
the global deficit score (GDS) [8] and the multivariate nor-
mative comparison (MNC) [9]. These criteria differ in the
* Correspondence: d.defrancesco@ucl.ac.uk
1Research Department of Infection & Population Health, UCL - Royal Free
Campus, London, UK
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
De Francesco et al. BMC Infectious Diseases  (2016) 16:617 
DOI 10.1186/s12879-016-1970-8
way they combine scores from a battery of neuropsycho-
logical tests to classify subjects as either cognitively im-
paired or normally functioning. Several studies have
reported contrasting results when using different criteria of
CI on the same set of patients [10, 11]. However, they only
assessed prevalence rates by criteria and did not specifically
investigate whether they identified the same people as
impaired/not impaired.
The associations between CI and patient-reported out-
comes of cognitive function have not been fully investi-
gated and remain unclear. Some studies have found a
relationship between subjective cognitive complaints and
actual impairment in neuropsychological tests [12, 13],
while other studies have not [14, 15]. While these studies
tended to include high rates of untreated or unsuppressed
subjects, there is currently a lack of data relating cognitive
function with self-reported cognitive complaints in popu-
lations of well-treated HIV-positive individuals.
The aims of this study are threefold. Firstly, to compare
the prevalence of CI in HIV-positive individuals over
50 years of age and demographically matched HIV-negative
controls according to the Frascati criteria, GDS and MNC
and combinations of these definitions. Secondly, to assess
the level of agreement between these three criteria when
identifying HIV-positive people with CI. Finally, to investi-
gate the association between different definitions of CI and
their combination with patient-reported symptoms of
cognitive dysfunction.
Methods
Study design and participants
The Pharmacokinetic and Clinical Observations in People
Over Fifty (POPPY) study is a prospective, multicentre, ob-
servational study that aims to examine the effects of ageing
on the clinical outcomes of people living with HIV in UK
and Ireland. To address its aims the study has established
cohorts of HIV-positive people aged over 50, younger
HIV-positive controls less than 50 years old and demo-
graphically matched HIV-negative controls aged over
50 years. For the present analysis only the two older
cohorts were considered as the purpose of the younger
HIV-positive cohort is to provide a younger control group
which is not directly relevant to this analysis. HIV-positive
participants were recruited at HIV outpatient clinics
around UK and Ireland. Inclusion criteria were: docu-
mented presence of HIV infection, self-defined white or
black-African ethnicity, likely route of HIV acquisition via
sexual exposure (either by male to male exposure if white
or by heterosexual exposure if white or black-African) and
ability to comprehend the study patient information leaflet.
HIV-negative controls were frequency matched to the
HIV-positive group on gender, ethnicity, sexual orientation
and location (in or out of London) and were recruited from
sexual health clinics affiliated with the HIV clinics, as well
as from community events, churches, adverts in targeted
publications and community groups. Recruitment was
from January 2013 to September 2014. The study was ap-
proved by the UK National Research Ethics Service (NRES;
Fulham London, UK number 12/LO/1409). Written in-
formed consent was obtained from all participants prior to
undertaking any study specific procedures.
Cognitive symptoms
All enrolled participants completed questionnaires de-
tailing physical and mental health status. In particular,
participants answered the three questions on cognitive
symptoms described by the EACS guidelines [5] regard-
ing memory loss (do you experience frequent memory
loss [e.g., do you forget the occurrence of special events
even the more recent ones, appointments, etc.]?), rea-
soning (do you feel that you are slower when reasoning,
planning activities, or solving problems?) and attention
(do you have difficulties paying attention [e.g., to a con-
versation, book or movie]?). Individuals answering ‘Yes,
definitely’, as opposed to ‘Never’ and ‘Hardly ever’ were
classified as experiencing the related cognitive symptom.
In addition a positive answer to at least two of the three
questions was considered indicative of self-reported cog-
nitive problems.
Assessment of cognitive function
Assessment of cognitive function was performed using the
CogState battery [16], a computerized battery of neuro-
psychological tests that has been used in different clinical
settings [17–20], including HIV-positive cohorts [21–24].
The battery covered six cognitive domains commonly af-
fected by HIV-associated CI, including visual learning,
psychomotor function, visual attention, executive func-
tion, verbal learning and working memory (see Additional
file 1: Table S1 for details of individual tests and how they
map onto cognitive domains). Raw test scores were log-
transformed or arcsine root–transformed where necessary
(as recommended by the CogState guidelines for analysis)
and converted into demographically-adjusted T scores
(with a mean of 50 and a standard deviation of 10) using
the scores of the HIV-negative group as normative scores.
Briefly, a linear regression was fit for each test in order to
estimate regression coefficients for age, gender, ethnicity
and education using scores from the HIV-negative group.
These regression coefficients were then used to determine
the normative scores depending on subjects’ age, gender,
ethnicity and education. The difference between the nor-
mative score and the actual score for each subject was
then standardized into T-scores. A single T-score was cal-
culated for each of the 6 cognitive domains by averaging
individual test T-scores within each domain. A global T-
score was also obtained by averaging T-scores across the
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six domains. For all T-scores a higher value indicates bet-
ter cognitive function.
Classification of CI
For each subject, the T-scores were then used to determine
if the individuals met three definitions of CI, Frascati, GDS
and MNC, using published methods. Frascati and GDS are
the most extensively adopted definitions in previous studies
of CI in HIV, while the MNC is a relatively newer approach
showing promising results in reducing the false positive rate
[10]. First, according to the Frascati criteria [7], CI was de-
fined as at least two cognitive domain T-scores below 40
(i.e., one or more standard deviations below the average
normative score). Second, a GDS [8] was computed for
each subject by converting domain T-scores into deficit
scores (0: T-score ≥ 40, 1: 34 < T-score < 40, 2: 29 < T-
score ≤ 34, 3: 24 < T-score ≤ 29, 4: 19 < T-score ≤ 24, 5: T-
score ≤ 19). An overall GDS was obtained by averaging
domain deficit scores and CI was defined as a mean score
equal or greater than 0.5. Finally, the MNC method [9] was
applied. The MNC is a statistical method that simultan-
eously compares multiple cognitive scores of each study
participant to the average scores of the same tests in the
control group (in our case the HIV-negative group), taking
into account the variances and covariance between all
scores. For each participant, a continuous measure of the
deviation of the participant’s cognitive profile from the aver-
age cognitive profile in the control group is then obtained.
If this deviation (also called Hotelling’s T2) exceeds a critical
value associated with a 5 % significance the individual is
classified as cognitively impaired (so that the chance of er-
roneously concluding that an individual has CI while this is
not the case, i.e., the false positive rate, is approximately
5 %). Definitions of CI included the three criteria listed
above plus all combinations of patients meeting individual
criteria and two or all three of these criteria.
Statistical analysis
Group comparisons of baseline characteristics were
assessed using Chi-square, Wilcoxon rank-sum and t-tests
(two-tailed) as appropriate. Comparisons of the prevalence
of CI in HIV-positive and HIV-negative persons were per-
formed using the Chi-square test with odds ratios used to
provide a comparative estimate of the prevalence in the
two groups. The agreement between criteria of CI was
assessed using Cohen’s κ statistics [25] and interpreted fol-
lowing Landis and Koch [26] guidelines. The null hypoth-
esis that Cohen’s κ equals zero (i.e., no agreement between
criteria other than what would be expected by chance) was
tested using the asymptotic test [27]. Internal consistency
between the three patient-reported cognitive problems was
assessed using Cronbach’s α. Associations between each
definition of CI and self-reported cognitive problems were
assessed using the Chi-square test. All analyses were
performed using SAS v9.4 with p-values <0.05 considered
as statistically significant.
Results
Participant characteristics
A total of 290 HIV-positive and 97 HIV-negative partici-
pants were enrolled into the study between January 2013
and September 2014 and completed the CogState battery.
Demographic, lifestyle and HIV-related characteristics are
summarised in Table 1. Groups were highly comparable in
terms of age (median age [IQR] was 57 [53, 62] and 58
[54, 62] years in HIV-positive and HIV-negative partici-
pants, respectively; p = 0.22), ethnicity (p = 0.47), country
of birth (p = 0.92), educational attainment (p = 0.14), alco-
hol consumption (p = 0.13) and smoking status (p = 0.79).
HIV-positive participants were more likely to be male
(88.3 % vs. 66.0 %, p < 0.01), gay or homosexual (71.7 % vs.
41.2 %, p < 0.01) and to have reported recreational drug
use in the 6 months preceding study entry (27.9 % vs.
12.4 %, p < 0.01) compared to HIV-negative controls.
HIV-positives had been diagnosed with HIV for a median
(IQR) of 16.8 (10.2, 22.9) years previously, and around
96.9 % were on ART with a median (IQR) CD4+ cell count
of 610 (478, 780) cells/μL.
Cognitive test results and prevalence of CI
Overall performance of HIV-positive subjects was poorer
than HIV-negative controls with a median (IQR) global T-
score of 48.6 (43.5, 52.3) compared to 50.8 (46.0, 55.7) for
the controls (p < 0.01). Significantly lower scores in the
HIV-positive group, as compared to the HIV-negative
group, were found for the cognitive domains: psycho-
motor function (median [IQR]: 48.4 [40.5, 54.4] vs 50.8
[45.4, 57.0], p < 0.01), visual attention (48.6 [39.7, 55.0] vs
50.9 [44.5, 57.0], p = 0.03) and verbal learning (47.0 [38.9,
53.6] vs 51.6 [45.3, 57.2], p < 0.01). In contrast, no signifi-
cant group difference was found for the cognitive domains
of visual learning (49.3 [42.7, 54.0] vs 50.8 [46.0, 55.7], p =
0.06), executive function (50.5 [45.9, 55.4] vs 50.4 [46.2,
54.8], p = 0.83) and working memory (50.1 [43.9, 54.4] vs
51.4 [46.0, 54.9], p = 0.15). The prevalence of CI in the
HIV-positive group varied from 34.5 % according to GDS,
30.0 % according to Frascati and 22.1 % for the MNC.
Similarly, the prevalence of CI varied in the HIV-negative
group from 14.4 % (GDS) to 16.5 % (Frascati) and 7.2 %
(MNC). According to all the three criteria, HIV-positive
participants were significantly more likely of having CI
than HIV-negative controls; OR (95 % CI) were 2.17
(1.20–3.92, p = 0.01) for Frascati, 3.12 (1.69–5.78, p < 0.01)
for GDS and 3.64 (1.61–8.24, p < 0.01) for MNC.
Agreement between definitions of CI
Overlap in the classification of CI between the three cri-
teria and Cohen’s κ statistics are reported in Fig. 1.
De Francesco et al. BMC Infectious Diseases  (2016) 16:617 Page 3 of 9
Table 1 Demographic, lifestyle and HIV-related characteristics of HIV-positive and HIV-negative study participants at enrolment
(IQR: interquartile range)
≥50 HIV-positive (N = 290) ≥50 HIV-negative (N = 97) p-value
Age [years], median (range) 57 (50, 82) 58 (50, 83) 0.22
Gender, n (%) <0.01
Female 34 (11.7 %) 33 (34.0 %)
Male 256 (88.3 %) 64 (66.0 %)
Ethnicity, n (%) 0.47
Black-African 37 (12.8 %) 9 (9.3 %)
White 253 (87.2 %) 88 (90.7 %)
Country of birth, n (%) 0.92
UK/Ireland 202 (69.7 %) 70 (72.2 %)
Rest of Europe 17 (5.9 %) 4 (4.1 %)
Africa 44 (15.2 %) 14 (14.4 %)
Rest of the world 27 (9.3 %) 9 (9.3 %)
Sexual orientation, n (%) <0.01
Gay/Homosexual 208 (71.7 %) 40 (41.2 %)
Bisexual 11 (3.8 %) 1 (1.0 %)
Straight/Heterosexual 56 (19.3 %) 50 (51.6 %)
Other/Unknown 15 (5.2 %) 6 (6.2 %)
Education, n (%) 0.14
No qualification 31 (10.7 %) 4 (4.1 %)
O levels/GCSEs (or equivalent at age 16) 41 (14.1 %) 18 (18.6 %)
A levels (or equivalent at age 18) 41 (14.1 %) 20 (20.6 %)
University degree or above 127 (43.8 %) 42 (43.3 %)
Other/Unknown 50 (17.2 %) 13 (13.4 %)
Smoking status, n (%) 0.79
Current smoker 70 (24.1 %) 20 (20.6 %)
Ex-smoker 108 (37.2 %) 37 (38.1 %)
Never smoked 111 (38.3 %) 39 (40.2 %)
Not known 1 (0.3 %) 1 (1.0 %)
Years of smoking (current/past smokers), median (IQR) 32 (20, 40) 33 (21, 40) 0.86
Alcohol consumption, n (%) 0.13
Current consumption 227 (78.3 %) 83 (85.6 %)
Previous consumption only 40 (13.8 %) 6 (6.2 %)
Never consumed alcohol 23 (7.9 %) 8 (8.3 %)
Recreational drugs in past 6 months, n (%) 83 (27.9 %) 12 (12.4 %) <0.01
Route of HIV-acquisition, n (%)
Sex between men and women 61 (21.0 %) N/A
Sex between men 229 (79.0 %) N/A
Years since HIV diagnosis, median (IQR) 16.8 (10.2, 22.9) N/A
CD4+ cell count at enrolment [cells/μL], median (IQR) 610 (478, 780) N/A
On antiretroviral treatment, n (%) 281 (96.9 %) N/A
Viral load <50 copies/mL, n (%) 263 (90.7 %) N/A
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Overall 169 (58.3 %) HIV-positive individuals did not
meet any of the three definitions of CI while 41 (14.1 %)
were classified as cognitively impaired by all the three
definitions. Thirty-six (12.4 %) met Frascati and GDS
only, 10 (3.4 %) met GDS and MNC only and 2 (0.7 %)
met Frascati and MNC only. Frascati and GDS showed a
substantial agreement (κ = 0.74, p < 0.01) while Frascati
and MNC, and GDS and MNC showed moderate agree-
ment (κ = 0.42 and κ = 0.48, respectively; p < 0.01 for
each). Definitions showed better agreement when tested
on the HIV-negative group: κ = 0.84 (p < 0.01) for Fras-
cati and GDS, κ = 0.57 (p < 0.01) for Frascati and MNC
and κ = 0.53 (p < 0.01) for GDS and MNC. Cognitive
scores in individual domains of HIV-positive individuals
meeting each of the three definition were similar (Fig. 2).
Association between definitions of CI and self-reported
cognitive problems
Overall, 14, 15 and 17 HIV-positive individuals did not an-
swer or had missing information on memory loss, reason-
ing and attention problems, respectively. Among those with
complete information, 79 (28.6 %) reported frequent mem-
ory loss, 105 (38.2 %) reported reasoning problems and 79
(28.9 %) attention problems; moreover 90 (32.5 %) reported
at least two of the three problems. Internal consistency of
the three patient-reported measures was excellent with a
Cronbach’s α (95 % CI) of 0.9 (0.82, 0.98). A significant as-
sociation was found between memory loss and all the three
definitions of CI (Table 2): using the Frascati criteria, 38 %
of subjects with CI reported frequent memory loss, while
only 25 % did so among those without CI (p = 0.02), with
Fig. 1 Classification of CI among HIV-positive individuals according to the three criteria and agreement between criteria in HIV-positive and
HIV-negative participants
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GDS the proportions were 40 and 23 % (p < 0.01) for those
with and without CI, respectively, and with MNC 41 and
25 % (p = 0.02). There was no strong evidence for associa-
tions between reasoning problems and self-reported
attention problems with definitions of CI, regardless of the
definition (Reasoning: p = 0.77, p = 0.24 and p = 0.42 for
Frascati, GDS and MNC, respectively; Attention: p = 0.59,
p = 0.07 and p = 0.28 for Frascati, GDS and MNC,
respectively).
Cognitive function and self-reported symptoms and
overlap between definitions of CI
Those meeting all three definitions (n = 41, 14.1 %) had a
low median global T-score (36.9, Fig. 3), indicating poorer
cognitive function, and approximately 41.5 % reported at
least two of memory loss, reasoning and attention prob-
lems. In particular, performances in the psychomotor (me-
dian score: 26) and visual attention (33.1) domains were
particularly poor. The 36 (12.4 %) subjects with CI accord-
ing to Frascati and GDS (but not MNC) demonstrated
similar cognitive function: 13 of them (36.1 %) reported at
least two cognitive problems and the median global T-
score was 41.9. On the other hand, the 11 (3.8 %) subjects
identified as cognitively impaired only by MNC performed
generally better (median global T-score equals to 48.0)
and a lower proportion (18.2 %) reported two or more
cognitive problems.
Discussion
HIV-positive individuals exhibit poorer cognitive func-
tion when compared to an appropriate HIV-negative
control group. Although the difference in the overall
cognitive score is statistically significant, this would not
be considered clinically meaningful (for T-scores, a 5-
point difference is usually considered relevant from a
clinical point of view [28]). The prevalence of CI in older
Fig. 2 Domain T-scores in HIV-positive individuals classified as cognitively impaired by the three criteria
Table 2 Frequency distribution (with row percentages) of memory loss, reasoning and attention problems by status of CI according
to the three criteria among HIV-positive individuals
Memory loss, n (%) Reasoning, n (%) Attention, n (%)
No Yes p No Yes p No Yes p
Frascati 0.02 0.77 0.59
CI 50 (62 %) 31 (38 %) 49 (60 %) 32 (40 %) 55 (69 %) 25 (31 %)
Not CI 147 (75 %) 48 (25 %) 121 (62 %) 73 (38 %) 139 (72 %) 54 (28 %)
GDS <0.01 0.24 0.07
CI 56 (60 %) 37 (40 %) 53 (57 %) 40 (43 %) 59 (64 %) 33 (36 %)
Not CI 141 (77 %) 42 (23 %) 117 (64 %) 65 (36 %) 135 (75 %) 46 (25 %)
MNC 0.02 0.42 0.28
CI 36 (59 %) 25 (41 %) 35 (57 %) 26 (43 %) 40 (66 %) 21 (34 %)
Not CI 161 (75 %) 54 (25 %) 135 (63 %) 79 (37 %) 154 (73 %) 58 (27 %)
14, 15 and 17 HIV-positive individuals had missing information on memory loss, reasoning and attention problems, respectively
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HIV-positive individuals may vary from 35 to 22 % de-
pending on the criteria used.
Commonly-used criteria of CI show fair agreement,
especially Frascati and GDS. However, this agreement is
mainly driven by the ability of criteria to exclude CI in
the same set of subjects rather than their ability to iden-
tify CI. As expected, subjects meeting all the criteria
have generally poorer cognitive function (with particu-
larly poor performances in the psychomotor and visual
attention domains) and are more likely to experience
cognitive problems. Similar cognitive scores were also
observed in subjects classified as impaired by Frascati
and GDS (but not MNC).
Consistent with several published studies [14, 15], but
contrary to others [12, 13], the associations with self-
reported cognitive symptoms are generally poor for all the
three definitions of CI considered. Whilst CI, defined with
all three criteria, correlate with memory loss, this is not the
case for either attention or reasoning problems. These re-
sults, based on a cohort of mainly treated and virally-
suppressed subjects, shed further light on the association
between patient-reported and objective cognitive impair-
ment in the post-ART era. The lack of association found
may reflect the pattern of cognitive changes we observed,
namely, poorer verbal learning (which may relate to patient
reported memory problems) but no significant differences
in executive function (reasoning) or working memory
(attention). These results suggest a potential lack of a clear
relationship between subjective measures of cognitive func-
tion and more objective measures based on neuropsycho-
logical tests, particularly in those with mild impairment.
Several reasons may account for this lack of association,
such as the over-reporting of cognitive symptoms and the
subjectivity of the EACS questions. Moreover, depressive
disorders have been previously reported to affect both
subjective and objective cognitive function [29], and can
therefore confound the association between the two. We
did not co-vary depression in our analyses, but from pre-
liminary analysis, depression did not seem to change the as-
sociations between definitions of CI and patient-reported
symptoms (data not shown).
A missing answer to questions about cognitive com-
plaints may, in theory, be informative as it may indicate
poor understanding or attention. However, almost 95 % of
data was complete so it’s unlikely that the exclusion of this
small group of individuals from analyses has introduced
substantial bias. Although ART prescribing was in line with
national guidelines, 3.1 % of enrolled HIV-positive individ-
uals were not receiving suppressive antiretroviral therapy at
study entry. This is justified by the aim of the study of
recruiting a ‘real-world’ sample of PLWH in UK and
Ireland. Nonetheless those not receiving ART had a median
CD4+ cell count of 664 cells/μL, which makes it unlikely
that lack of suppression of HIV replication in a minority of
the sample has led to substantial bias to our findings.
Given the lack of a gold standard in defining CI, it is
difficult to ascertain the validity of different definitions.
An optimal definition of CI would capture subjects with
the lowest cognitive performance scores and the greatest
number of cognitive symptom complaints. In our study
we observed the lowest overall cognitive score in sub-
jects meeting all three definitions (median global T-
score of 36.9 for those meeting Frascati, MNC and
GDS). Moreover, in this group of subject, the number
reporting cognitive complaints was highest (41.5 %).
Given these findings, we consider further work to assess
longitudinal outcomes in HIV-positive individuals
meeting this definition of CI within the POPPY study,
compared to other definitions of cognitive impairment,
is justified.
Fig. 3 Median global T-score (a) and proportion of subjects reporting two or more cognitive problems (b) by subset of HIV-positive participants
meeting different combinations of the three definitions of CI
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Other definitions of cognitive impairment in PLWH,
such as the Frascati criteria, have been criticised for over-
calling the number of PLWH with cognitive deficits [11].
On the converse argument, the Frascati criteria has
attempted to define the presence of cognitive deficits prior
to the onset of clinical symptomatology and classifies large
numbers of subjects with CI. The rationale behind such
criteria being interventions at an early stage of disease, if
effective, may prevent the onset of clinically apparent con-
ditions. However, to date, longitudinal data both in the
HIV-field and in other neurodegenerative diseases have
not provided convincing evidence for the diagnosis of a
pre-morbid cognitive state [30, 31].
There are several other problems when utilising non-
stringent definitions of CI. Firstly, as large numbers of pa-
tients will meet a diagnostic criteria, unnecessary anxiety
for patients could be created. Secondly, non-stringent def-
initions will include subjects with cognitive impairment
but will also include subjects who do not have cognitive
impairment. Within interventional trials, this may lead to
the null hypothesis being proven when in fact an interven-
tion does work. By including patients without a disease
state in an interventional study, the results of the study
may suggest an effective interventions has no effect
whereas, if the effective intervention was trialled in the
diseased population, an effect may be observed.
Conclusions
Commonly-used criteria of CI show fair agreement,
especially in identifying subjects without CI. However
their association with patient-reported symptoms is gen-
erally weak and we hypothesise that our POPPY Study
definition of cognitive impairment may be a pragmatic
approach to adopt at the current time. Our definition,
by defining subjects with the highest rates of symptom-
atology and the lowest global cognitive score is likely to
capture patients with true pathological cognitive impair-
ment and requires validation within other HIV-cohorts
and in longitudinal settings.
Additional file
Additional file 1: Table S1. Cognitive tests administered by cognitive
domain. (DOCX 13 kb)
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